Longevity Docs (newsletter)
Longevity Medicine Enters Adulthood: 'Back to Medicine' and the End of the Wild West
A sector maturity signal: less hype, more real medicine — protocols, traceability, and clinical oversight.
Latest
Longevity Medicine News
Research, clinical trials, regulatory updates, and industry analysis from the longevity medicine world.
ARPA-H Peer-reviewed
ARPA-H Commits $144 Million to the First Clinical Trials Designed to Extend Healthspan
The U.S. government's ARPA-H launches the PROSPR program: $144M over five years to identify early aging biomarkers and run the first clinical trials explicitly aimed at extending healthy lifespan.
ArentFox Schiff (press release)
When an Am Law 100 Firm Creates a 'Longevity & Healthspan' Group, It's No Longer Niche
An Am Law 100 firm launches a group dedicated to longevity/healthspan: a signal that regulation, privacy, and IP are becoming the real battleground.
The Washington Post Peer-reviewed
The Washington Post on Longevity Medicine's Boom: Big Promises, Uncertain Evidence
The Washington Post investigates the longevity medicine boom — from biohacking expos to high-end clinics — finding that commercial fervor has outpaced both scientific evidence and federal regulation.
EMA — CAT Quarterly Highlights (Dec 2025) Peer-reviewed
Advanced Therapies in Europe (ATMPs): What the EMA Is Approving and Why It Matters for Longevity Clinics
The EMA publishes its quarterly ATMP report (Jun–Nov 2025): cell, gene, and tissue therapy. A key regulatory signal for clinics offering stem cells or regenerative therapies.
Aging-US Peer-reviewed
Longevity Clinics Between Promise and Peril: What a Leading Journal's Editor-in-Chief Thinks
An editorial in Aging by its Editor-in-Chief reviews the rapid rise of longevity clinics worldwide, highlighting both their potential for data-driven innovation and the serious risks of cost, standardization gaps, and scientific disconnect.